Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females, aged 18 to 65 years, inclusive, at time of informed consent~* Able to understand and comply with the protocol~* Must be English or French speaking~* At the investigator's opinion, must be willing and able to perform self-injections into the right and left thighs with the single-use autoinjector~Exclusion Criteria:~* Abnormal screening blood tests determined to be clinically significant by the Investigator~* Treatment with any systemic anticoagulant within the previous 30 days~* Treatment with aspirin within the previous 7 days or nonsteroidal anti-inflammatory drugs (NSAIDs) within the previous 3 days~* History of severe allergic or anaphylactic reactions~* History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, pyschiatric, renal, and/or other major disease including bleeding disorders~* Current enrollment in any other investigational study~* Female subjects who are currently pregnant~* History of alcohol or substance abuse or a positive drug screening test on day 1~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- All subjects to self-administer 4 IM injections (Type: EXPERIMENTAL): Subjects will be recruited and stratified into BMI groups: \<18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and \>30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.

Based on this trial design, predict the completion outcome and termination type (if applicable).